Alexander Wiseman, MD
Transplant Surgery · Denver, CONPI 1033209713
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Veloxis Pharmaceuticals, Inc. at 38.1% of the total. Reporting peaked in 2023 at $51,750 and has fallen 52.0% since, to $24,857 in 2025. Among transplant surgery clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $1068.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veloxis Pharmaceuticals, Inc.$68K
- Sanofi-aventis U.S. LLC$45K
- Takeda Pharmaceuticals U.S.A., Inc.$38K
- Mallinckrodt Enterprises LLC$11K
- Immucor, Inc.$4K
- Biogen$3K
- plus $8K from 15 others
Across 25 payments — averaging $5843.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$57K
- Novartis$56K
- E.r. Squibb & Sons, L.L.C.$33K
What the payments were for
- Consulting fees$67,63238%
- Speaking & faculty fees$91,61052%
- Grants$7500%
- Travel & lodging$13,4958%
- Food & beverage$3,9632%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veloxis Pharmaceuticals, Inc. | 44 | $67,598 |
| Sanofi-aventis U.S. LLC | 44 | $45,249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $38,474 |
| Mallinckrodt Enterprises LLC | 5 | $11,128 |
| Immucor, Inc. | 1 | $3,750 |
| Biogen | 1 | $3,080 |
| Mallinckrodt Hospital Products Inc. | 3 | $2,657 |
| Amgen | 5 | $2,220 |
| Calliditas Therapeutics US Inc. | 3 | $2,219 |
| Merck | 4 | $686 |
| AstraZeneca | 4 | $87 |
| Madrigal Pharmaceuticals | 2 | $68 |
| Astellas Pharma US Inc | 3 | $56 |
| Novo Nordisk | 1 | $35 |
| Eisai Inc. | 1 | $27 |
| Acera Surgical, Inc. | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Orphalan Inc | 1 | $19 |
| Invivyd Inc | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Envarsus$67,148
- THYMOGLOBULIN$43,266
- LIVTENCITY$38,043
- CELLEX/XTS PHOTOPHERESIS SYSTEM$7,976
- ACTHAR$3,113
- CELLEX$2,627
- TARPEYO$2,197
- KRYSTEXXA$2,055
How this compares
$177,450 in reported general payments places this provider in the 95th percentile of 22 transplant surgery providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $16,890 |
| Tacrolimus | 43 | $11,366 |
| Valganciclovir Hcl | 24 | $8,207 |
| Mycophenolic AcidMycophenolate Sodium | 19 | $1,949 |
| Dapsone | 16 | $590 |
| Atorvastatin Calcium | 95 | $462 |
| Labetalol Hcl | 15 | $424 |
| Losartan Potassium | 42 | $405 |
| Carvedilol | 40 | $388 |
| Pantoprazole Sodium | 37 | $338 |
| Prednisone | 61 | $294 |
| Amlodipine Besylate | 41 | $273 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $219 |
| Lisinopril | 39 | $150 |
| Furosemide | 12 | $104 |
Paid to pharmacies, not to this prescriber.
Other transplant surgery in Denver
- Thomas HeffronDenver$18K
- Giuseppe D'amicoDenver$12K
- Daniel KuehlerDenver$7K
- Oya AndacogluDenver$4K
- Thomas CollinsDenver$2K
- James LimDenver$877
- Massimo AsolatiDenver$743
- Thomas PshakAurora$33K
- Peter KennealeyAurora$31K
- Hunter MooreAurora$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.